| Treatment patterns and survival in metastatic castration‐sensitive prostate cancer in the US Veterans Health Administration SJ Freedland, R Sandin, J Sah, B Emir, Q Mu, A Ratiu, A Hong, L Serfass, ... Cancer medicine 10 (23), 8570-8580, 2021 | 43 | 2021 |
| Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a US claims data analysis A Cohen, A Keshishian, T Lee, G Wygant, L Rosenblatt, P Hlavacek, ... Thrombosis and Haemostasis 121 (03), 383-395, 2021 | 42 | 2021 |
| Effectiveness and safety of apixaban vs. warfarin in venous thromboembolism patients with obesity and morbid obesity A Cohen, J Sah, T Lee, L Rosenblatt, P Hlavacek, B Emir, A Keshishian, ... Journal of Clinical Medicine 10 (2), 200, 2021 | 33 | 2021 |
| Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States F Kariburyo, L Xie, J Sah, N Li, JH Lofland Journal of Medical Economics 23 (1), 1-9, 2020 | 27 | 2020 |
| Effectiveness and safety of apixaban versus warfarin in venous thromboembolism patients with chronic kidney disease AT Cohen, J Sah, AD Dhamane, T Lee, L Rosenblatt, P Hlavacek, B Emir, ... Thrombosis and Haemostasis 122 (06), 926-938, 2022 | 26 | 2022 |
| Persistence, dosing, and other treatment patterns among Crohn’s disease patients initiating biologics in United States A Teeple, J Sah, R Mallampati, C Adams, D Waters, E Muser Crohn's & Colitis 360 3 (4), otab076, 2021 | 13 | 2021 |
| 679P Treatment patterns of metastatic castration-sensitive prostate cancer (mCSPC): a real-world evidence study ST Tagawa, R Sandin, J Sah, Q Mu, SJ Freedland Annals of Oncology 31, S541-S542, 2020 | 12 | 2020 |
| Effectiveness and safety of Apixaban versus warfarin in obese patients with Nonvalvular atrial fibrillation enrolled in Medicare and veteran affairs S Deitelzweig, J Sah, A Kang, C Russ, M Preib, AD Dhamane, A Ratiu, ... The American Journal of Cardiology 163, 43-49, 2022 | 10 | 2022 |
| Effectiveness and safety of apixaban versus warfarin among older patients with venous thromboembolism with different demographics and socioeconomic status AT Cohen, J Sah, AD Dhamane, T Lee, L Rosenblatt, P Hlavacek, B Emir, ... Advances in Therapy 38, 5519-5533, 2021 | 10 | 2021 |
| Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases J Sah, A Teeple, E Muser, C Gutierrez, T Dassopoulos Current Medical Research and Opinion 38 (7), 1093-1101, 2022 | 9 | 2022 |
| Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer AT Cohen, A Keshishian, T Lee, L Rosenblatt, P Hlavacek, J Sah, X Luo Current Medical Research and Opinion 37 (9), 1467-1482, 2021 | 9 | 2021 |
| The atrial fibrillation real world management registry in the middle East and Africa: design and rationale MA Sobhy, M Khoury, WA Almahmeed, J Sah, M Di Fusco, J Mardekian, ... Journal of Cardiovascular Medicine 21 (9), 704-710, 2020 | 8 | 2020 |
| Comparative clinical and economic outcomes associated with warfarin versus apixaban in the treatment of patients with venous thromboembolism in a large US commercial claims … JD Guo, J Rajpura, P Hlavacek, A Keshishian, J Sah, R Delinger, Q Mu, ... Journal of Managed Care & Specialty Pharmacy 26 (8), 1017-1026, 2020 | 8 | 2020 |
| Evaluating the effect of standard of care treatment on burden of chronic hepatitis B: a retrospective analysis of the United States veterans population U Sbarigia, F Kariburyo, J Sah, J Colasurdo, L Xie, EG Katz, S Sylvester Advances in Therapy 37, 1156-1172, 2020 | 8 | 2020 |
| Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study. SJ Freedland, R Sandin, J Sah, B Emir, Q Mu, A Ratiu, A Hong, L Serfass, ... Journal of Clinical Oncology 39 (6_suppl), 46-46, 2021 | 6 | 2021 |
| Effectiveness and safety of apixaban vs warfarin in patients with venous thromboembolism with risk factors for bleeding or for recurrences AT Cohen, J Sah, AD Dhamane, DM Hines, T Lee, L Rosenblatt, B Emir, ... Advances in Therapy 40 (4), 1705-1735, 2023 | 5 | 2023 |
| Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding AT Cohen, J Sah, AD Dhamane, T Lee, L Rosenblatt, P Hlavacek, B Emir, ... PLoS One 17 (9), e0274969, 2022 | 4 | 2022 |
| Safety and effectiveness of apixaban, LMWH, and warfarin among venous thromboembolism patients with active cancer: a retrospective analysis using four US claims databases AT Cohen, A Keshishian, T Lee, G Wygant, L Rosenblatt, P Hlavacek, ... Blood 134, 326, 2019 | 4 | 2019 |
| Effectiveness and safety of apixaban, low-molecular weight heparin, and warfarin among high-risk subgroups of venous thromboembolism patients with active cancer A Cohen, A Keshishian, T Lee, G Wygant, L Rosenblatt, P Hlavacek, ... Eur Heart J 41 (Supplement_2), ehaa946. 3369, 2020 | 3 | 2020 |
| FRI0201 REAL WORLD MEDICATION USE IN INCIDENT SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS PATIENTS L Xie, F Kariburyo, J Sah, JH Lofland, LI Nan Annals of the Rheumatic Diseases 78 (Suppl 2), 779-780, 2019 | 2 | 2019 |
Allison KeshishianSTATinMED Research在 statinmed.com 的电子邮件经过验证
